Trial
NCT03107052
A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Cluster Headache
Intervention
Fremanezumab
Why stopped
The study was terminated after the episodic cluster study was terminated due to a pre specified futility analyses
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09